Pharmacokinetics of Levofloxacin in Intensive Care Unit

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is 1. to describe levofloxacin pharmacokinetics in ICU patients suffering from pneumonia with taking into account physio-pathological parameters. 2. to verify clinical and bacteriological efficiency and to know if the peak/Minimum Inhibitory Concentration (MIC) ratio \> 5 and Area Under Curve (AUC) /Minimum Inhibitory Concentration(MIC) ratio \> 125. No therapeutic drug monitoring will be performed in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia

NCT00253955

Pneumonia

COMPLETED PHASE3

A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia

NCT00257049

Pneumonia

COMPLETED PHASE2/PHASE3

Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia

NCT00429975

Pneumonia, Pneumococcal

TERMINATED PHASE4

A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization

NCT00236834

Nosocomial Pneumonia

COMPLETED PHASE3

Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects

NCT02253342

Intrapulmonary Pharmacokinetics of WCK 2349

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intensive Care Unit Syndrome Community-acquired Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Levofloxacin

Population having a community-acquired pneumonia of which the indication of the treatment is administration of Levofloxacin

Group Type EXPERIMENTAL

Levofloxacin

Intervention Type DRUG

8 blood sampling by patients between the 48th and 60th

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Levofloxacin

8 blood sampling by patients between the 48th and 60th

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

pharmacokinetic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* severe community-acquired pneumonia due to a strain sensible to levofloxacin
* Age \> 18 years
* Informed consent
* SAPS II (simplified acute physiological score) \> 20 Awaited duration of survival higher than 7 days